All prescription plans are required to offer Medication Therapy Management (MTM) services. Although MTM is aimed at optimizing therapy, including the efficient and effective use of medications, this service, unfortunately, is limited to the following Medicare beneficiaries:
Even though Medicare beneficiaries entering the doughnut hole, by definition, will have met at least one of these requirements, many of them might not meet all three requirements. In addition, MTM programs are directed by each prescription drug plan, so the process varies by program.
Because prescription plans are not affected financially by Medicare beneficiaries within the doughnut hole, many plans may not find it worthwhile to aggressively manage the expenditures of these members. As a result, this responsibility is likely to fall upon other providers, such as physicians and pharmacists, although consultant pharmacists are best suited for this task.
One of the most overlooked opportunities for patients to delay entry into the doughnut hole is to take advantage of the low-income subsidy. For Medicare beneficiaries with limited income and resources, a significant subsidy of their premiums and out-of-pocket expenses is available. Instead of the major gap that exists for most Medicare beneficiaries, low-income individuals pay only a $50 deductible instead of $250 and a 15% copayment instead of the 100% copayment if they have fallen into the doughnut hole.
Even with this significant benefit, a large number of Medicare beneficiaries have not taken advantage of the subsidy. Social workers and others may be able to identify eligible individuals and assist them through the enrollment process. Enrollment is provided through either Social Security or Medicaid programs.
Pharmaceutical assistance programs can provide extra help in paying for medications; however, many of these programs have stopped providing coverage because of concerns about fraud and abuse raised by the DHHS’s Office of the Inspector General (OIG). These concerns stem from the possibility that branded products could be promoted over the use of less expensive, which could save Medicare resources.
In November 2006, AstraZeneca announced a new program that may offer convenient savings for Medicare Part D enrollees. Medicare patients who qualify and enroll will be able to go to their participating local pharmacy and receive savings on AstraZeneca products immediately. Enrollees in the current AstraZeneca program pay no more than $25 for a typical 30-day supply of covered medications that are available through Medicare Part D. A typical 60-day retail supply costs no more than $37.50, and a typical 90-day retail supply costs no more than $50. Qualifications for participating in the AstraZeneca program are as follows:
The DHHS’s OIG has issued a favorable advisory opinion concerning AstraZeneca’s program and affirms that the company’s extension of coverage to Medicare Part D beneficiaries is consistent with OIG guidelines. Other pharmaceutical companies may extend similar coverage to “at-need” Medicare beneficiaries. canadian pharmacy online
In the end, the doughnut hole is a dangerous place to be for patients, providers, and pharmaceutical companies. It is possible to avoid falling into it with the help of astute clinical and health policy expertise, something that has been limited until now in the debate and management of Medicare Part D.